MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin.
BACKGROUND
MGN-3/Biobran, a modified form of arabinoxylan from rice bran, is a potent biological response modifier (BRM). Our previous studies demonstrated that MGN-3 sensitizes human leukemia cells to death receptor [CD95]-induced apoptosis [Ghoneum M, Gollapudi S. MGN-3 sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 2003;201:41-9]. In this study, we evaluated the chemo-sensitizing activity of MGN-3 against human breast cancer cells (BCCs) in vitro.


METHODS
BCCs (MCF-7 and HCC70 cells) were cultured with different concentrations of daunorubicin (DNR) (from 1x10(-9) to 1x10(-6)M) in the presence or absence of selected concentrations of MGN-3 (100-1000mug/ml) for 3 days. Cancer cell survival was determined by MTT assay and drug accumulation was determined by flow cytometry.


RESULTS
Treatment with MGN-3 increased susceptibility of BCCs to DNR (5.5-fold for MCF-7 and 2.5-fold for HCC70 cells) as compared to BCCs treated with DNR alone. The sensitizing effect of MGN-3 was associated with increased accumulation of DNR in cancer cells.


CONCLUSIONS
Our data demonstrate that MGN-3 is an effective chemo-sensitizer and may represent a potential novel adjuvant for the treatment of breast cancer.
Gollapudi
Sastry
S
University of California at Irvine, Division of Basic and Clinical Immunology, Irvine, CA 92697, USA.
Ghoneum
Mamdooh
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002470:Cell Survival; D017024:Chemotherapy, Adjuvant; D003630:Daunorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D014990:Xylans / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014990:Xylans; C419427:polysaccharide MGN3; D003630:Daunorubicin